Treatment of EGFR-TKI for Residual Lesions of Multiple Synchronous Ground-glass Opacities
Condition: Multiple Primary Lung Cancers Interventions: Drug: furmonertinib; Drug: Placebo Sponsors: Ruijin Hospital; Fujian Medical University Union Hospital; First Affiliated Hospital of Zhejiang University; Second Affiliated Hospital, School of Medicine, Zhejiang University; Tang-Du Hospital; The First Affiliated Hospital of Nanchang University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials